- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07626151
Electric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy
Effect Of Standard Versus Restricted Fluid Therapy Guided By Electric Cardiometry On Tissue Perfuison In Robotic Prostaectomy: A Randomized Controlled Study
Fluid therapy during surgery is an important factor that is related to long term mortality and morbidity and it's directly related to tissue perfusion as well. The main target in any surgery is what is the optimum fluid therapy to maintain the tissue perfusion and the precise balance between hazardous effects of hypervolemia that may cause delayed wound healing due to surgical anastomosis disruption or being hypovolemic that may cause tissue ischemia as acute kidney injury.
Fluid management guidance changed from static methods like central venous pressure into dynamic methods like pulse pressure variation (PPV) and stroke volume variation (SVV), which are now the most famous dynamic measures.
Electrical cardiometry is a non-invasive cardiac output monitor which uses electrical cardiometry, now a commonly used device, to measure SVV which can be used to guide fluid therapy during surgeries.
Now robotic assisted surgery is a common method in preforming many surgeries especially urological, since it's associated with numerous desirable outcomes including shorter post-operative stay and faster return to preoperative function.
With considerations related to severe Trendelenburg position and increased intra-abdominal pressure due to pneumo-peritoneum, robotic assisted surgeries are associated with many challenges in anesthesia especially the fluid therapy.
Fluid therapy in robotic surgeries is an area with growing research focus that need further exploration while there are established guidelines for fluid management in traditional surgeries, the optimal protocols for robotic surgeries are less well defined, needing more research.
We aim at this study to investigate the impact of liberal versus restricted fluid intake on the tissue perfusion reflected by serum lactate & creatinine clearance, while guiding therapy through electrical cardiometry, to reach optimum fluid protocol in prostatic robotic surgeries.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Mohamed M Mohamed, M.Sc.
- Telefonnummer: +20 111 8370641
- E-post: mandamembo0@gmail.com
Studer Kontakt Backup
- Navn: Nazmy S Mikhael, M.D.
- Telefonnummer: +20122 7400808
- E-post: drnazmyseif@kasralainy.edu.eg
Studiesteder
-
-
-
Cairo, Egypt
- Rekruttering
- Cairo University Hospitals
-
Ta kontakt med:
- Mohamed M Mohamed, M.Sc.
- Telefonnummer: +20 111 8370641
- E-post: mandamembo0@gmail.com
-
Ta kontakt med:
- Nazmy S Mikhael, M.D.
- Telefonnummer: +201227400808
- E-post: drnazmyseif@kasralainy.edu.eg
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Male patient undergoing robotic assisted prostatectomy
- ASA I-III
Exclusion Criteria:
- ASA score more than III
- BMI more than 40
- Severe renal disease (GFR between 15 and 29)
- Previous renal surgery.
- Decompensated cardiac disease (NYHA class 3 or 4)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Liberal Group
Liberal Fluid Therapy Group
|
Patients will receive 6 ml/kg/hour of lactated ringer for maintenance in addition to fasting hours compensation (2 ml/kg for each fasting hour, given as 50% in the first hour of surgery, then 25% during the second & third hours).
An additional bolus of 200 ml Lactated Ringer will be given if MAP is below 65 mmHg.
In case of persistent hypotension despite proper fluid rescuistation, 10 mg of Ephedrine will be administered; if no response is achieved, norepinerhine infusion will start at initial dose 0.01mcg/kg/min if MAP is below 65 mmHg.
|
|
Aktiv komparator: Restricted Group
Restricted Fluid Therapy Group
|
Patients will receive 2 ml/kg as fluid bolus then 2 ml/kg/hour for maintenance, aiming at a target SVV less than 13 %.
Patients with SVV ≥ 13% will be considered fluid responder and will receive a fluid bolus of 200 ml Ringer Lactated Ringer over 10 minutes.The fluid bolus will be repeated until the SVV is less than 13%.
In case of persistent hypotension (MAP less than 65mmHg), 10 mg of Ephedrine will be administered; if no response is achieved, norepinerhine infusion will be started at intial dose 0.01mcg/kg/min if MAP is below 65 mmHg.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum Lactate level difference
Tidsramme: 24 hours
|
Serum Lactate level difference between pre-operative (baseline) value and post-operative (recovery) value in mmol/L
|
24 hours
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Ashgan R Aly, M.D., Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University
- Hovedetterforsker: Nazmy S Mikhael, M.D., Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University
- Studieleder: Mohamed M Mohamed, M.Sc., Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Genitale neoplasmer, hanner
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kjønnssykdommer, mannlige
- Prostata sykdommer
- Mannlige urogenitale sykdommer
- Metabolske sykdommer
- Patologiske tilstander, tegn og symptomer
- Ernæringsmessige og metabolske sykdommer
- Tegn og symptomer
- Prostatiske neoplasmer
- Ødem
- Hyperlaktatemi
Andre studie-ID-numre
- ECGSVRFTRP
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Liberal Fluid Therapy
-
Karaman Training and Research HospitalFullført
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI); National Institute of...FullførtHjertesvikt, kongestivForente stater
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Har ikke rekruttert ennåPasienter med radiologisk, klinisk og anamnestisk bilde forenlig med en ny diagnose av glioblastom
-
Bicetre HospitalRekruttering
-
University of EdinburghNHS Lothian; Chief Scientist Office of the Scottish Government; Transfusion...FullførtAnemi | Blodoverføring | IntensivenStorbritannia
-
Ondokuz Mayıs UniversityFullførtPeriodontale sykdommer | Nevrogen betennelse | Periimplantat sykdommer | Gingival Crevicular Fluid | Periimplantat sulkulær væske
-
Hospital NordRekrutteringEvaluering av variasjonen av sub-pulmonal hastighet-tid integral for å forutsi væskens reaksjonsevneFluid Responsibility Forutsigbarhet | Væske gjenopplivingFrankrike
-
Nova Scotia Health AuthorityFullført
-
Nanogen, Inc.Centers for Disease Control and PreventionSuspendert
-
Alexandria UniversityAktiv, ikke rekrutterende